Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZALEA
2024-514031-20-00Phase 2Authorised
- Sponsor
- European Institute of Oncology
- Start
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, vinorelbine and cyclophosphamide in triple-negative breast cancer (TNBC), sponsored by European Institute of Oncology. Primary endpoint: overall response rate. Planned start Aug 2024; status: authorised.
02
Drugs
atezolizumabvinorelbinecyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-514031-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514031-20-00.